QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 wells-fargo-maintains-overweight-on-mineralys-therapeutics-raises-price-target-to-50

Wells Fargo analyst Mohit Bansal maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Overweight and raises the price targe...

 goldman-sachs-maintains-buy-on-mineralys-therapeutics-raises-price-target-to-52

Goldman Sachs analyst Richard Law maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and raises the price target from...

 hc-wainwright--co-reiterates-buy-on-mineralys-therapeutics-maintains-42-price-target

HC Wainwright & Co. analyst Matthew Caufield reiterates Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and maintains $4...

 mineralys-therapeutics-presents-subgroup-data-from-phase-3-launch-htn-trial-at-aha-2025-highlighting-lorundrostats-efficacy-in-high-risk-hypertension-populations

~Pivotal Launch-HTN trial of novel aldosterone synthase inhibitor lorundrostat enrolled a diverse range of participants with un...

 jefferies-maintains-hold-on-mineralys-therapeutics-raises-price-target-to-26

Jefferies analyst Dennis Ding maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Hold and raises the price target from $1...

 mineralys-therapeutics-suspends-prospectus-supplement-for-atm-equity-offering

-SEC Filing

 mineralys-therapeutics-commences-175m-public-offering-with-2625m-over-allotment-option

Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to targe...

 b-of-a-securities-maintains-buy-on-mineralys-therapeutics-raises-price-target-to-43

B of A Securities analyst Greg Harrison maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and raises the price targe...

 hc-wainwright--co-reiterates-buy-on-mineralys-therapeutics-maintains-42-price-target

HC Wainwright & Co. analyst Matthew Caufield reiterates Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and maintains $4...

 nasdaq-100-sp-500-hit-new-all-time-highs-airlines-jump-whats-moving-markets-tuesday

Wall Street is in full rally mode after July’s inflation data eased fears that tariff-related cost pressures were widespread. T...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION